|
|
Article: Lab21 Ltd to Provide AdnaGen's CE-Marked System for the Detection and Analysis of Circulating Tumor Cells CTCs in the United Kingdom and Ireland.(Company overview)
- Article from:
- Cancer Weekly
- Article date:
- August 25, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Lab21 Ltd and AdnaGen AG announced that they have entered into an exclusive service and distribution agreement for AdnaGen's proprietary CE-certified circulating tumor cell diagnostic assays in the United Kingdom and Ireland. These tests are based on the capture of circulating tumor cells (CTCs) from blood and subsequent detection of tumor-associated biomarkers. Cancer diagnostics is a fast evolving and rapidly growing segment of in-vitro diagnostics. The high prevalence and mortality rates rank cancer amongst the world's most disabling and deadly diseases. Cancer is the second most deadly condition, affecting over 25 million people worldwide, with more than 10 million new ...